Paul Newhouse, MD, Vanderbilt Center for Cognitive Medicine, Nashville, TN, discusses whether cholinergic agents will be beneficial beyond treatment of mild cognitive impairment (MCI), as seen in the ongoing MIND study (NCT02720445). It is not yet known whether cholinergic treatments, such as nicotinic stimulation, will be effective in later stages of Alzheimer’s disease (AD). However, cholinergic systems have been shown to deteriorate with AD progression and therefore nicotinic stimulation may not be effective. One approach may be to combine other selective cholinergic agonists with nicotine treatment. For example, combining nicotinic stimulation with cholinesterase inhibitors has been shown to have a positive effect on AD patients. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Prof. Newhouse reports the following disclosures: I am a consultant to PMI Inc.